Page last updated at 07:30 GMT, Wednesday, 4 February 2009

Kidney cancer drug gets go-ahead

NICE's Andrew Dillon explains the decision

The NHS drugs watchdog NICE has in principle approved a kidney cancer drug which can increase survival by a year.

Sunitinib is one of the first drugs to be approved under new guidance urging a more liberal approach to treatments which only marginally extend life.

The decision applies to England and Northern Ireland. Wales has already approved the drug, but it is still not available in Scotland.

NICE's chief executive Andrew Dillon said it had listened to the public.

"Many people have made the point very strongly that they regard the ability of the NHS to extend life as being of special importance," he told the BBC.

"And so we looked at the way our advisory committees go about valuing extension to life.

Flexibility

This is a victory for kidney cancer patients and is long overdue
Rachel Rowson
Macmillan Cancer Support

"We wanted to make sure that they had enough flexibility in all circumstances to make a recommendation where drugs have the ability to give people some additional life."

Sunitinib, known commercially as Sutent, was originally rejected last year for the treatment of advanced kidney cancer along with three other drugs.

Final advice on the use of these three drugs - as well as sunitinib - will be issued in March.

The National Institute for Health and Clinical Excellence said it took into account the offer of the manufacturer, Pfizer, to provide the first cycle of sunitinib free to the NHS when making its decision.

The average daily cost of sunitinib is about 75, with an average six-week cycle costing in excess of 3,000.

Early last month, NICE agreed to extend the threshold at which drugs for terminally ill patients are deemed cost-effective.

Last year renal cancer experts criticised draft proposals to deny four treatments to patients with advanced kidney cancer, because they only extended life by a matter of months.

NICE said that while Avastin (bevacizumab), Nexavar (sorafenib), Sutent (sunitinib) and Torisel (temsirolimus) provided "significant gains" in survival, they did not meet cost effectiveness criteria.

Welcome step

But doctors said it left them with few options to treat the 1,700 people diagnosed every year with the advanced form of the disease.

The approval of sunitinib has been welcomed by doctors, although they stress there are some patients who are not suited to the drug and would do better on one of the other three.

"It's not for everyone, and particularly those with cardiovascular problems," said Professor Tim Eisen, a kidney cancer specialist at the University of Cambridge.

"But this is a very welcome step."

Rachel Rowson, policy manager at Macmillan Cancer Support, said: "This is a victory for kidney cancer patients and is long overdue.

"This decision recognises the need to fund drugs that improve quality of life for patients and we applaud Nice for making Sutent available to all who need it.

"Macmillan will continue to campaign to ensure the other three drugs for kidney cancer are also approved for use on the NHS."

Professor Peter Johnson, of Cancer Research UK, said sunitinib could "make an important difference" for people who have few other options for treatment.

But he called on NICE to decide on the remaining three drugs as quickly as possible - and ensure one or more was made available to patients.

Earlier this month, the Welsh health minister Edwina Hart announced that all four kidney cancer drugs would be made available to people in Wales.

However, this decision may be reviewed when NICE announces its final decision on all four drugs.



Print Sponsor


SEE ALSO
Insurers eye NHS top ups market
15 Oct 08 |  Health

RELATED INTERNET LINKS
The BBC is not responsible for the content of external internet sites


FEATURES, VIEWS, ANALYSIS
Has China's housing bubble burst?
How the world's oldest clove tree defied an empire
Why Royal Ballet principal Sergei Polunin quit

BBC navigation

BBC © 2014 The BBC is not responsible for the content of external sites. Read more.

This page is best viewed in an up-to-date web browser with style sheets (CSS) enabled. While you will be able to view the content of this page in your current browser, you will not be able to get the full visual experience. Please consider upgrading your browser software or enabling style sheets (CSS) if you are able to do so.

Americas Africa Europe Middle East South Asia Asia Pacific